BIOGRAPHICAL SKETCH
Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. DO NOT EXCEED FOUR PAGES.
NAME POSITION TITLE
Barry London Harry S. Tack Professor of Medicine
eRA COMMONS USER NAME Chief, Division of Cardiology
londonb Director, Cardiovascular Institute
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)
DEGREE
INSTITUTION AND LOCATION YEAR(s) FIELD OF STUDY
(if applicable)
Harvard College, Cambridge MA A.B. 1980 Chemistry & Physics
Hebrew College B.J.Ed. 1980 Hebrew Literature
Albert Einstein College of Medicine, Bronx NY MS,MD,PhD 1984,87,87 Physiol/Biophys, Med
Massachusetts General Hospital, Boston MA 1987-93 Int Med Res;Card Fellow
Children’s Hospital, Boston MA & HHMI 1992-94 Research Card Fellow
APPOINTMENTS:
1993 - 1995 Instructor in Medicine, Harvard Medical School, Boston MA
1993 - 1995 Clinical Assistant in Medicine, Staff Cardiologist, Massachusetts General Hospital, Boston MA
1994 - 1996 Assistant in Cardiology, Children’s Hospital, Boston MA
1995 Assistant in Medicine, Massachusetts General Hospital, Boston MA
1996 - 2001 Assistant Professor in Medicine, University of Pittsburgh, Pittsburgh PA
2001 - 2006 Associate Professor in Medicine, Cell Biology & Physiology, University of Pittsburgh, PA
2002 - 2003 Assistant Dean of Admissions, University of Pittsburgh School of Medicine, Pittsburgh, PA
2003 - Chief, Division of Cardiology & Director, Cardiovascular Institute, University of Pittsburgh, PA
2006 - Harry S. Tack Professor of Medicine, Cell Biology & Physiology, University of Pittsburgh, PA
HONORS & GRANTS:
1979; 1980 Phi Beta Kappa; Magna Cum Laude, Harvard College
1983 Samuel and May Rudin Scholarship, Albert Einstein College of Medicine
1984 -1987 Medical Scientist Training Program, Albert Einstein College of Medicine
1987 Alpha Omega Alpha, Albert Einstein College of Medicine
1992 - American Heart Association Fellowship, Grant-in-Aid, Established Investigator
1992 -1993 Howard Hughes Medical Institute Fellowship, Children’s Hospital, Boston
1993 -1998 Clinical Development Investigator Award, NIH NHLBI; Charles H. Hood Fdn Child Health Grant
1997 -1998 Competitive Medical Research Fund Grant, University of Pittsburgh Medical Center
1998 Fellow, American College of Cardiology; Astra-Merck Cardiovasc Young Invest Award, 2nd Place
2003; 2005 Member, American Society for Clinical Investigation; Member, Assn of University Cardiologists
LICENSURE & CERTIFICATION:
1989; 1995 Massachusetts; Pennsylvania License Registration (Medicine)
1990; 1993 Board Certification in Internal Medicine; Cardiovascular Medicine
BIBLIOGRAPHY (Selected Articles)
1. London B, Krueger JW. Contraction in voltage-clamped, internally perfused single heart cells. J Gen Physiol
1986; 88: 475-505.
2. London B, Trudeau MC, Newton KP, Beyer AK, Copeland NG, Gilbert DJ, Jenkins NA, Satler CA, Robertson
GA. Two isoforms of the mouse ether-a-go-go related gene coassemble to form channels with properties
similar to the rapidly activity component of the cardiac delayed rectifier K+ current. Cir Res 1997; 81: 870-8.
3. London B, Jeron A, Zhou J, Buckett P, Han X, Mitchell GF, Koren G. Long QT and ventricular arrhythmias
in transgenic mice expressing the N-terminus and first transmembrane segment of a voltage-gated
potassium channel. Proc Natl Acad Sci (USA) 1998; 95: 2926-2931.
4. London B, Wang DW, Hill JA, Bennett PG. The transient outward current (Ito) in targeted mice lacking Kv1.4.
J Physiol (London) 1998; 509: 171-182.
5. Baker LC, London B, Choi B-R, Koren G, Salama G. Enhanced dispersion of repolarization and refractori-
ness in transgenic mouse heart promotes reentrant ventricular tachycardia. Circ Res 2000; 86: 396-407.
6. McNamara DM, Holubkov R, Janosko K, Palmer A, Wang JJ, MacGowan GA, Murali S, Rosenblum WD,
London B, Feldman AM. Pharmacogenetic interactions between β blocker therapy & the angiotensin con-
verting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 2000;103:1644-8
7. London B, Guo W, Pan X-H, Lee JS, Shusterman V, Rocco CJ, Logothetis DA, Nerbonne JM, Hill JA.
Targeted replacement of Kv1.5 in the mouse leads to loss of the 4-aminopyridine-sensitive component of
IK,slow and resistance to drug-induced QT prolongation. Circ Res 2001; 88: 940-946.
8. Weiss R, Barmada MM, Nguyen T, Seibel JS, Cavlovich D, Kornblit CA, Angelilli A, Villanueva F,
McNamara DM, London B. Clinical and molecular heterogeneity in the Brugada syndrome: A novel gene
locus on chromosome 3. Circulation 2002; 105: 707-713.
9. Shusterman V, Usiene I, Harrigal C, Lee JS, Kubota T, Feldman AM, London B. Strain-specific patterns of
cardiac rhythm and autonomic nervous system activity in mice. Amer J Physiol 2002; 282: H2076-2083.
10. London B, Baker LC, Lee JS, Shusterman V, Choi B-R, Kubota T, McTiernan CF, Feldman AM, Salama B.
Calcium-dependent arrhythmias in transgenic mice with heart failure. Amer J Physiol 2003; 284: H431-441.
11. McNamara DM, Holubkov R, Postava L, Ramani R, Janosko K, Mathier M, MacGowan GA, Murali S,
Feldman AM, London B. The Asp298 variant of endothelial nitric oxide synthase: Effect on survival for
patients with congestive heart failure. Circulation 2003; 107: 1598-1602.
12. Bedi M, Postava LA, Murali S, MacGowan GA, Mathier M, Shears L, Kormos R, Holubkov R, London B,
McNamara DM. The effect of the TNF-α polymorphism on cardiac allograft rejection. J Heart Lung
Transplant 2004; 23: 696-700.
13. Bedi MS, Postava LA, Murali S, MacGowan GA, Mathier M, McNamara DM, London B. ICD implantation
does not decrease the ACE-dependent genetic risk in heart failure. J Cardio Electrophys 2004;15:1162-6.
14. Saba S, Shusterman V, Usiene I, London B. Cardiac autonomic modulation by estrogen in female mice un-
dergoing ambulatory monitoring & in vivo electrophysiologic testing. Ann Non-Inv Electrocard 2004; 9:142-8.
15. McNamara DM, Holubkov R, Postava L, Janosko K, MacGowan GA, Mathier M, Murali S, Feldman AM,
London B. The ACE deletion polymorphism modulates the effect of neurohormonal blockade on heart failure
survival. J Am Col Cardiol 2004; 44: 2019-2026.
16. Chen H-H, Baty CJ, Maeda T, Brooks S, Baker LC, Ueyama T, Gursoy E, Saba S, Salama G, London B,
Stewart AFR. RTEF-1 transgenic mice develop cardiac conduction defects associated with altered connexin
phosphorylation. Circulation 2004; 110: 2980-2987.
17. Saba S, Janczewski AM, Baker LC, Shusterman V, Gursoy EC, Salama G, Feldman AM, McTiernan CF,
London B. Atrial contractile dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy
secondary to cardiac-specific overexpression of tumor necrosis factor-α. Am J Physiol 2005; 289:H1456-66.
18. Hreybe H, Ezzeddine R, Bedi M, Barrington W, Bazaz R, Ganz LI, Jain S, Ngwu O, London B, Saba S.
Renal insufficiency predicts the time to first appropriate defibrillator shock. Amer Heart J 2005; 151: 852-6.
19. Petkova-Kirova PS, Gursoy E, Mehdi H, London B, Salama G. Electrical remodeling of cardiac myocytes
from mice with heart failure due to the over-expression of TNF α. Am J Physiol 2006; 290: H2098-H2107.
20. Wang X, Hockerman GH, Green HW, Babbs CF, Mohammad SI, Gerrard D, Latour MA, London B, Hannon
KM, Pond AL. Merg1a K+ channel function induces skeletal muscle atrophy by activating the ubiquitin
porteasome pathway. FASEB J 2006; 20: 1531-1533.
21. Bedi M, McNamara DM, London B, Schwartzman D. Genetic susceptibility to atrial fibrillation in patients with
congestive heart failure. Heart Rhythm 2006; 3: 808-812
22. Shusterman V, Goldberg A, London B. Upsurge in T-wave alternans & non-alternating repolarization instab-
ility precedes spontaneous initiation of ventricular tachyarrhythmias in humans. Circulation 2006;113:2880-7
23. London, B, Baker, LC, Petkova-Kirova, P, Nerbonne, JM, Choi, B-R, Salama, G. Dispersion of repolarization
and refractoriness are determinants of arrhythmia phenotype in transgenic mice with long QT. J Physiol
(London) 2007; 578: 115-129.
24. Pfahnl AD, Viswanathan PC, Weis R, Shang LL, Sanyal S, Shusterman V, Kornblit C, London B, Dudley
SC. A sodium channel pore mutation causing Brugada syndrome. Heart Rhythm 2007; 4: 46-53.
25. London B, Albert C, Anderson ME, Giles WR, Van Wagoner DR, Balk E, Billman GE, Chung M, Lands W,
Leaf A, McAnulty J, Martens JR, Costello RB, Lathrop DA. Omega-3 Fatty Acids and Cardiac Arrhythmias:
Prior Studies and Recommendations for Future Research. A Report from the NHLBI and ODS Omega-3
Fatty Acids and their Role in Cardiac Arrhythmogenesis Workshop. Circulation 2007; 116: e320-e335.
26. London B, Michalec M, Mehdi H, Zhu X, Kerchner L, Sanyal S, Viswanathan PC, Pfahn AE, Shang LL,
Madhusudanan M, Baty CJ, Lagana S, Aleong R, Gutmann R, Ackerman MJ, McNamara DM, Weis R, and
Dudley SC Jr. A mutation in GPD1-L decreases cardiac Na+ current and causes inherited arrhythmias.
Circulation 2007; 116: 2260-2268.
27. Van Norstrand DW, Valdivia CR, Tester DJ, Ueda K, London B, Makielski C, Ackerman MJ. Molecular and
functional characterization of novel GPD1-L mutations in sudden infant death syndrome. Circulation 2007;
116: 2253-2259.
28. McTiernan CF*, Mathier MA*, Zhu X, Xiao X, Klein E, Swan CH, Mehdi H, Gibson G, Trichel AM, Glorioso
JC, Feldman AM, McCurry KR, London B. Myocarditis Following Adeno-Associated Viral Gene Expression
of Human Soluble TNF Receptor (TNFRII-Fc) in Baboon Hearts. Gene Therapy 2007; 14: 1613-1622.
29. Saba S, Mathier MA, Mehdi H, Gursoy E, Liu T, Choi B-R, London B, Salama G. Dual-dye optical mapping
after myocardial infarction. Does the site of ventricular stimulation alter the properties of electrical
propagation? Journal of Cardiovasc Electrophys 2008; In Press.
30. Saba S, Mathier MA, Mehdi H, Gursoy E, Liu T, Choi B-R, Salama G, London B. Prevention of adverse
electrical and mechanical remodeling with bi-ventricular pacing in a rabbit model of myocardial infarction.
Heart Rhythm 2008; In Press.
RESEARCH PROJECTS ONGOING OR COMPLETED DURING THE LAST 3 YEARS:
1. A Clinical and Molecular Analysis of the Brugada Syndrome (PHS-R01 HL62300, PI London, 1999-2011).
Project to study the clinical characteristics of a large family with an inherited arrhythmia and to identify the
gene that is responsible.
2. Mechanisms of Cytokine-Induced Arrhythmias in CHF (PHS-R01 HL60032, PI-Feldman, 1998-2001; PHS-
R01 HL 66096, PI London, 2001-2005). Project to characterize arrhythmias in a TNF-α transgenic model of
CHF.
3. Gene Transfer During LVAD Support (PHS-U01 HL66949, PI-Glorioso, Project 1 PI-London, 2002-2007);
Pivotal Toxicology Study of AAV6-SERCA2a in a Heart Failure Model (National Gene Vector Lab, 2006-
2008); Project to use test the safety and efficacy of gene therapy for heart failure in large animals and
humans.
4. Genetic Modulation of Left Ventricular Recovery (PHS-R01 HL75038, PI McNamara, Co-Inv London, 2003-
2008). Project will identify the role of genetic polymorphisms in predicting recovery from acute
cardiomyopathies.
5. Gender-Differences in Cardiac Repolarization / Arrhythmias (PHS-R01 HL70722, PI Salama, Co-Inv
London, 2002-2006). Project to define gender differences in expression and spatial distribution of ion
channels in the hearts of rabbits.
6. Genetic Modulators of Sudden Death (PHS-R01 HL077398, PI London, 2004-2009). Project to identify
genetic determinants of arrhythmias in patients with cardiomyopathies.
8. Transgenic Mouse Models of Arrhythmias (AHA EI 0540048N, PI London, 2005-2009). Project to identify
the genetic determinants of T-wave alternans using transgenic and knockout mice.